



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

November 10, 2020

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on September 30, 2020.

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular nos. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find

1. Standalone unaudited financial results for the quarter ended on September 30, 2020 accompanied by limited review report; and
2. Consolidated unaudited financial results for the quarter ended on September 30, 2020 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 16.28 p.m. and concluded at 17.56 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary and Vice President - Compliance

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2020

(₹ in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half year ended		Year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	41,177.85	48,962.43	42,812.42	90,140.28	83,892.47	164,074.44
2	Other Income	818.78	2,253.54	1,810.70	3,072.32	3,044.45	4,934.27
3	Total Income (1+2)	41,996.63	51,215.97	44,623.12	93,212.60	86,936.92	169,008.71
4	Expenses						
a.	Cost of materials consumed	15,204.58	12,657.83	10,619.99	27,862.41	23,237.73	45,210.43
b.	Purchases of stock-in-trade	1,302.57	4,292.54	4,497.95	5,595.11	5,863.36	11,450.09
c.	Changes in inventories of finished goods, work-in- progress and stock-in-trade	(4,387.47)	(441.65)	176.96	(4,829.12)	1,183.39	252.83
d.	Employee benefit expenses	7,302.88	8,154.15	6,969.05	15,457.03	14,033.16	29,378.09
e.	Finance Costs	169.59	373.12	87.43	542.71	167.80	293.51
f.	Depreciation and amortization expense	1,714.01	1,696.73	1,622.32	3,410.74	3,185.23	6,509.05
g.	Other Expenses	11,181.64	8,484.04	10,471.86	19,665.68	20,272.74	40,958.54
	Total Expenses (4)	32,487.80	35,216.76	34,445.56	67,704.56	67,943.41	134,052.54
5	Profit before Exceptional item and Tax (3-4)	9,508.83	15,999.21	10,177.56	25,508.04	18,993.51	34,956.17
6	Exceptional item (Refer Note no. 5)	-	-	-	-	-	1,000.00
7	Profit before Tax (5-6)	9,508.83	15,999.21	10,177.56	25,508.04	18,993.51	33,956.17
8	Tax expenses	2,410.52	3,806.68	581.63	6,217.20	3,482.94	7,141.77
9	Net Profit after Tax for the period (7-8)	7,098.31	12,192.53	9,595.93	19,290.84	15,510.57	26,814.40
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss	(461.44)	(150.00)	(336.77)	(611.44)	(344.77)	(676.74)
	Income tax relating to Items that will not be reclassified to profit or loss	116.14	37.75	83.97	153.89	86.77	170.32
	Other Comprehensive Income (net of Tax)	(345.30)	(112.25)	(252.80)	(457.55)	(258.00)	(506.42)
11	Total Comprehensive Income after Tax (9+10)	6,753.01	12,080.28	9,343.13	18,833.29	15,252.57	26,307.98
12	Paid up equity Share Capital(Face value of ₹ 2 each)	1,545.64	1,545.64	1,604.73	1,545.64	1,604.73	1,545.64
13	Other Equity	-	-	-	-	-	142,983.44
14	Earning per share (not annualised)						
	(1) Basic in ₹	9.18	15.78	11.96	24.96	19.33	33.70
	(2) Diluted in ₹	9.18	15.78	11.96	24.96	19.33	33.70

Notes:

- The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 10, 2020. The results of the Company are available for investors at www.jbcpl.com, www.nseindia.com and www.bseindia.com.
- The statutory auditors have carried out limited review of the financial results for the quarter ended on September 30, 2020 and their report does not contain any qualification.
- Pursuant to the Share Purchase Agreement (SPA) dated 2nd July 2020 between Tau Investment Holdings Pte. Ltd. (the 'Acquirer') and the Promoter Group (the 'Seller'), the Acquirer has completed the process of open offer made in compliance with Regulation 3(1) and Regulation 4 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and consequently, the Seller has transferred agreed number of shares in favor of the Acquirer and the Acquirer now holds 54% of the controlling stake in the Company.
- During the quarter, the Company has acquired Pharmaceutical Business Undertaking of Lekar Pharma Limited, a related party, as going concern, on slump sale basis for a consideration of Rs. 8.50 crores having net current assets of Rs. 4.18 crores and sales revenue of Rs. 56.38 crores for the year ended March 31, 2020.
- Exceptional item appearing in the results for the quarter ended on March 31, 2020 relates to deposit of one-time compensation ordered by the Supreme Court vide judgement dated 1-4-2020 in appeal filed by the Company against Order dated 8-1-2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle. The Company has since paid this compensation.
- With announcement of phased lifting of lockdown by the Government in the country, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine may take time and hence, the Company continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its Standalone financial statements. The Company has also considered impact of Covid-19 pandemic on future operations and financial projections. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 5500
☎ +91 22 2431 5331 / 5334
@ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

7 The Code on Social Security, 2020 (the "Code") has been enacted. The date of coming into force of the various provisions of the Code is yet to be notified and the rules thereunder are yet to be announced. The potential impact of the change will be estimated and accounted in the period of notification.

8 The Company has only one reportable business segment viz. "Pharmaceuticals"

9 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

10 STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2020.

		(₹ in lakhs)	
	Particulars	As at September 30,2020	As at March 31,2020
		Unaudited	Audited
	ASSETS		
(I)	Non-current assets		
	(a) Property, Plant and Equipment	55,955.10	56,533.49
	(b) Capital work-in-progress	1,563.79	1,616.69
	(c) Goodwill	431.92	-
	(d) Other Intangible assets	1,790.22	1,787.22
	(e) Financial Assets		
	(i) Investments	14,593.27	20,242.13
	(ii) Loans	327.50	28.10
	(iii) Others	7.68	13.24
	(f) Other non-current assets	617.37	353.58
	TOTAL non-current assets	75,286.85	80,574.44
(II)	Current assets		
	(a) Inventories	32,356.98	23,203.82
	(b) Financial Assets		
	(i) Investments	44,738.54	33,381.26
	(ii) Trade receivables	40,310.50	34,423.91
	(iii) Cash and cash equivalents	1,997.23	962.27
	(iv) Bank balances other than (iii) above	198.51	194.02
	(v) Loans	67.75	401.88
	(vi) Others	1,171.28	721.07
	(c) Current Tax Assets (Net)	989.02	1,391.19
	(d) Other current assets	6,689.55	5,847.54
	TOTAL current assets	128,519.36	100,526.96
	Total Assets	203,806.21	181,101.40
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	1,545.64	1,545.64
	(b) Other Equity	161,816.72	142,983.44
	Total Equity	163,362.36	144,529.08
(I)	LIABILITIES		
	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Other financial liabilities	705.42	109.37
	(b) Provisions	1,978.01	738.68
	(c) Deferred Tax Liabilities (Net)	5,847.89	5,884.58
	(d) Other non-current liabilities	518.05	596.84
	TOTAL non-current Liabilities	9,049.37	7,329.47
(II)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	3,056.99	3,203.61
	(ii) Trade payables		
	A) Dues to Micro and Small Enterprises	846.30	945.29
	B) Due to Other than Micro and Small Enterprises	11,536.85	10,189.73
	(iii) Other financial liabilities	10,398.62	11,152.61
	(b) Other current liabilities	3,534.44	2,676.68
	(c) Provisions	321.17	472.88
	(d) Current Tax Liabilities (Net)	1,700.11	602.05
	TOTAL Current Liabilities	31,394.48	29,242.85
	Total Equity and Liabilities	203,806.21	181,101.40

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

11 Standalone Cash Flow Statement for six months ended 30th September, 2020

(₹ in lakhs)

Particulars	For the period ended Sept 2020		2019-20	
	Unaudited		Audited	
A. Cash Flow from Operating Activities				
Net Profit before Tax		25,508.04		33,956.17
Adjustment For				
Depreciation	3,410.74		6,509.05	
Unrealised Foreign Exchange Fluctuation (Net)	(132.00)		97.10	
Interest Expense	528.91		259.46	
(Profit)/ Loss on Sale/Discard of Assets (Net)	70.97		(166.24)	
Profit on sale of Investment designated as FVTPL	(941.57)		(2,501.30)	
Net (Gain)/Loss arising from Financial instruments designated as FVTPL	(1,758.44)		(1,298.40)	
Interest Income	(135.21)		(138.53)	
Dividend Income	(0.50)		(148.04)	
Government Grant	(82.66)		(91.14)	
Re-measurement of the defined benefit plan	(611.44)		(676.74)	
Excess provision written back	(223.09)		(416.48)	
Discontinuance of Leased Assets	(7.19)		-	
Provision for Doubtful debts/ Bad debts	-		90.52	
		118.52		1,519.26
Operating Profit Before Working Capital Changes		25,626.56		35,475.43
Adjustment For				
Trade Receivables	(5,802.22)		(4,392.01)	
Other Receivables	(1,265.16)		2,500.56	
Inventories	(9,153.15)		(2,393.41)	
Trade Payable	1,308.00		(162.73)	
Other Payables & Provisions	1,700.38		4,844.59	
		(13,212.15)		397.00
Cash Generated From Operations		12,414.41		35,872.43
Direct Taxes Paid (Net)		(4,599.77)		(8,715.26)
Net Cash from Operating Activities		7,814.64		27,157.17
B. Cash Flow from Investing Activities				
Purchase of Fixed Assets	(2,413.99)		(7,172.87)	
Sale of Fixed Assets	0.30		234.22	
Goodwill on purchase of business from Lekar Pharma Ltd.	(431.92)		-	
Purchase of Investment	(17,999.77)		(38,267.56)	
Sale of Investment	14,991.35		47,393.12	
(Increase)/Decrease in other bank balances	(4.49)		(53.99)	
Interest Received	139.32		136.97	
Dividend Received	0.50		148.04	
Net Cash used in Investing Activities		(5,718.70)		2,417.93

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

C. Cash Flow from Financing Activities				
Buy back of shares	-		(16,081.90)	
Proceeds/(Repayment) from/of Short Term Borrowing (Net)	14.35		631.40	
Interest Paid	(507.51)		(186.49)	
Dividend Paid (Including Dividend Distribution Tax)	(0.09)		(14,100.31)	
Lease Rent payment	(394.50)		(811.09)	
Net Cash Used in Financing Activities		(887.75)		(30,548.39)
Net Increase in Cash and Cash Equivalents		1,208.19		(973.29)
Cash and Cash Equivalents as at 01.04.20*	636.67		1,611.25	
Exchange difference on restatement of foreign currency cash and cash equivalent	(1.06)		(1.29)	
Cash and Cash Equivalents as at 30.09.20*	1,843.80	1,208.19	636.67	(973.29)

*Cash and Cash Equivalents comprises the following

Particulars	As at Sept 30,2020	As at March 31,2020
Balances with banks	1,392.23	924.21
Remittance in Transit	-	9.95
Cash on hand	29.31	22.40
Fixed Deposits with maturity of less than 3 months	575.69	5.71
	1,997.23	962.27
Less : Bank Overdraft	153.43	325.60
Cash and Cash Equivalents	1,843.80	636.67

Note: The Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.

X

Nikhil Chopra

Chief Executive Officer & Whole-time director

Date : 10/11/2020

Place : Mumbai

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Independent Auditors' Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of the J. B. Chemicals and Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
J. B. Chemicals and Pharmaceuticals Limited

- 1) We have reviewed the accompanying Statement of Unaudited Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Company"), for the quarter ended September 30, 2020 and for the year to date period from April 1, 2020 to September 30, 2020 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), which has been initialed by us for the purpose of Identification.
- 2) The Statement, which is the responsibility of the Company's management and approved by the Board of Directors in their respective meeting held on November 10, 2020 have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a opinion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4) Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and management principles laid down in aforesaid Indian Accounting Standard ("Ind AS") and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D N V & Co.
Chartered Accountants
Firm Registration No 102079W


CA Bharat Jain
Partner
Membership No: 100583
UDIN: 20100583AAAAGB3735



Place: Mumbai
Date: November 10, 2020



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2020

(₹ in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half year ended		Year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	41,177.85	48,962.43	42,812.42	90,140.28	83,892.47	164,074.44
2	Other Income	818.78	2,253.54	1,810.70	3,072.32	3,044.45	4,934.27
3	Total Income (1+2)	41,996.63	51,215.97	44,623.12	93,212.60	86,936.92	169,008.71
4	Expenses						
a.	Cost of materials consumed	15,204.58	12,657.83	10,619.99	27,862.41	23,237.73	45,210.43
b.	Purchases of stock-in-trade	1,302.57	4,292.54	4,497.95	5,595.11	5,863.36	11,450.09
c.	Changes in inventories of finished goods, work-in- progress and stock-in-trade	(4,387.47)	(441.65)	176.96	(4,829.12)	1,183.39	252.83
d.	Employee benefit expenses	7,302.88	8,154.15	6,969.05	15,457.03	14,033.16	29,378.09
e.	Finance Costs	169.59	373.12	87.43	542.71	167.80	293.51
f.	Depreciation and amortization expense	1,714.01	1,696.73	1,622.32	3,410.74	3,185.23	6,509.05
g.	Other Expenses	11,181.64	8,484.04	10,471.86	19,665.68	20,272.74	40,958.54
	Total Expenses (4)	32,487.80	35,216.76	34,445.56	67,704.56	67,943.41	134,052.54
5	Profit before Exceptional item and Tax (3-4)	9,508.83	15,999.21	10,177.56	25,508.04	18,993.51	34,956.17
6	Exceptional item (Refer Note no. 5)	-	-	-	-	-	1,000.00
7	Profit before Tax (5-6)	9,508.83	15,999.21	10,177.56	25,508.04	18,993.51	33,956.17
8	Tax expenses	2,410.52	3,806.68	581.63	6,217.20	3,482.94	7,141.77
9	Net Profit after Tax for the period (7-8)	7,098.31	12,192.53	9,595.93	19,290.84	15,510.57	26,814.40
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss	(461.44)	(150.00)	(336.77)	(611.44)	(344.77)	(676.74)
	Income tax relating to items that will not be reclassified to profit or loss	116.14	37.75	83.97	153.89	86.77	170.32
	Other Comprehensive Income (net of Tax)	(345.30)	(112.25)	(252.80)	(457.55)	(258.00)	(506.42)
11	Total Comprehensive Income after Tax (9+10)	6,753.01	12,080.28	9,343.13	18,833.29	15,252.57	26,307.98
12	Paid up equity Share Capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,604.73	1,545.64	1,604.73	1,545.64
13	Other Equity	-	-	-	-	-	142,983.44
14	Earning per share (not annualised)						
(1)	Basic in ₹	9.18	15.78	11.96	24.96	19.33	33.70
(2)	Diluted in ₹	9.18	15.78	11.96	24.96	19.33	33.70

Notes:

- The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 10, 2020. The results of the Company are available for investors at www.jbcpl.com, www.nseindia.com and www.bseindia.com.
- The statutory auditors have carried out limited review of the financial results for the quarter ended on September 30, 2020 and their report does not contain any qualification.
- Pursuant to the Share Purchase Agreement (SPA) dated 2nd July 2020 between Tau Investment Holdings Pte. Ltd. (the 'Acquirer') and the Promoter Group (the 'Seller'), the Acquirer has completed the process of open offer made in compliance with Regulation 3(1) and Regulation 4 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and consequently, the Seller has transferred agreed number of shares in favor the Acquirer and the Acquirer now holds 54% of the controlling stake in the Company.
- During the quarter, the Company has acquired Pharmaceutical Business Undertaking of Lekar Pharma Limited, a related party, as going concern, on slump sale basis for a consideration of Rs. 8.50 crores having net current assets of Rs. 4.18 crores and sales revenue of Rs. 56.38 crores for the year ended March 31, 2020.
- Exceptional item appearing in the results for the quarter ended on March 31, 2020 relates to deposit of one-time compensation ordered by the Supreme Court vide judgement dated 1-4-2020 in appeal filed by the Company against Order dated 8-1-2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle. The Company has since paid this compensation.
- With announcement of phased lifting of lockdown by the Government in the country, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine may take time and hence, the Company continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its Standalone financial statements. The Company has also considered impact of Covid-19 pandemic on future operations and financial projections. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 5500
☎ +91 22 2431 5331 / 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1978PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

7 The Code on Social Security, 2020 (the "Code") has been enacted. The date of coming into force of the various provisions of the Code is yet to be notified and the rules thereunder are yet to be announced. The potential impact of the change will be estimated and accounted in the period of notification.

8 The Company has only one reportable business segment viz. "Pharmaceuticals"

9 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

10 STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2020.

(₹ in lakhs)

Particulars	As at September 30,2020	As at March 31,2020
	Unaudited	Audited
ASSETS		
(I) Non-current assets		
(a) Property, Plant and Equipment	55,955.10	56,533.49
(b) Capital work-in-progress	1,563.79	1,616.69
(c) Goodwill	431.92	-
(d) Other Intangible assets	1,790.22	1,787.22
(e) Financial Assets		
(i) Investments	14,593.27	20,242.13
(ii) Loans	327.50	28.10
(iii) Others	7.68	13.24
(f) Other non-current assets	617.37	353.58
TOTAL non-current assets	75,286.85	80,574.44
(II) Current assets		
(a) Inventories	32,356.98	23,203.82
(b) Financial Assets		
(i) Investments	44,738.54	33,381.26
(ii) Trade receivables	40,310.50	34,423.91
(iii) Cash and cash equivalents	1,997.23	962.27
(iv) Bank balances other than (iii) above	198.51	194.02
(v) Loans	67.75	401.88
(vi) Others	1,171.28	721.07
(c) Current Tax Assets (Net)	989.02	1,391.19
(d) Other current assets	6,689.55	5,847.54
TOTAL current assets	128,519.36	100,526.96
Total Assets	203,806.21	181,101.40
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	1,545.64	1,545.64
(b) Other Equity	161,816.72	142,983.44
Total Equity	163,362.36	144,529.08
LIABILITIES		
(I) Non-current liabilities		
(a) Financial Liabilities		
(i) Other financial liabilities	705.42	109.37
(b) Provisions	1,978.01	738.68
(c) Deferred Tax Liabilities (Net)	5,847.89	5,884.58
(d) Other non-current liabilities	518.05	596.84
TOTAL non-current Liabilities	9,049.37	7,329.47
(II) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3,056.99	3,203.61
(ii) Trade payables		
A) Dues to Micro and Small Enterprises	846.30	945.29
B) Due to Other than Micro and Small Enterprises	11,536.85	10,189.73
(iii) Other financial liabilities	10,398.62	11,152.61
(b) Other current liabilities	3,534.44	2,676.68
(c) Provisions	321.17	472.88
(d) Current Tax Liabilities (Net)	1,700.11	602.05
TOTAL Current Liabilities	31,394.48	29,242.85
Total Equity and Liabilities	203,806.21	181,101.40



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

11 Standalone Cash Flow Statement for six months ended 30th September, 2020

(₹ in lakhs)

Particulars	For the period ended Sept 2020		2019-20	
	Unaudited		Audited	
A. Cash Flow from Operating Activities				
Net Profit before Tax		25,508.04		33,956.17
Adjustment For				
Depreciation	3,410.74		6,509.05	
Unrealised Foreign Exchange Fluctuation (Net)	(132.00)		97.10	
Interest Expense	528.91		259.46	
(Profit)/ Loss on Sale/Discard of Assets (Net)	70.97		(166.24)	
Profit on sale of Investment designated as FVTPL	(941.57)		(2,501.30)	
Net (Gain)/Loss arising from Financial instruments designated as FVTPL	(1,758.44)		(1,298.40)	
Interest Income	(135.21)		(138.53)	
Dividend Income	(0.50)		(148.04)	
Government Grant	(82.66)		(91.14)	
Re-measurement of the defined benefit plan	(611.44)		(676.74)	
Excess provision written back	(223.09)		(416.48)	
Discontinuance of Leased Assets	(7.19)		-	
Provision for Doubtful debts/ Bad debts	-		90.52	
		118.52		1,519.26
Operating Profit Before Working Capital Changes		25,626.56		35,475.43
Adjustment For				
Trade Receivables	(5,802.22)		(4,392.01)	
Other Receivables	(1,265.16)		2,500.56	
Inventories	(9,153.15)		(2,393.41)	
Trade Payable	1,308.00		(162.73)	
Other Payables & Provisions	1,700.38		4,844.59	
		(13,212.15)		397.00
Cash Generated From Operations		12,414.41		35,872.43
Direct Taxes Paid (Net)		(4,599.77)		(8,715.26)
Net Cash from Operating Activities		7,814.64		27,157.17
B. Cash Flow from Investing Activities				
Purchase of Fixed Assets	(2,413.99)		(7,172.87)	
Sale of Fixed Assets	0.30		234.22	
Goodwill on purchase of business from Lekar Pharma Ltd.	(431.92)		-	
Purchase of Investment	(17,999.77)		(38,267.56)	
Sale of Investment	14,991.35		47,393.12	
(Increase)/Decrease in other bank balances	(4.49)		(53.99)	
Interest Received	139.32		136.97	
Dividend Received	0.50		148.04	
Net Cash used in Investing Activities		(5,718.70)		2,417.93



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

C. Cash Flow from Financing Activities				
Buy back of shares	-		(16,081.90)	
Proceeds/(Repayment) from/of Short Term Borrowing (Net)	14.35		631.40	
Interest Paid	(507.51)		(186.49)	
Dividend Paid (Including Dividend Distribution Tax)	(0.09)		(14,100.31)	
Lease Rent payment	(394.50)		(811.09)	
Net Cash Used in Financing Activities		(887.75)		(30,548.39)
Net Increase in Cash and Cash Equivalents		1,208.19		(973.29)
Cash and Cash Equivalents as at 01.04.20*	636.67		1,611.25	
Exchange difference on restatement of foreign currency cash and cash equivalent	(1.06)		(1.29)	
Cash and Cash Equivalents as at 30.09.20*	1,843.80	1,208.19	636.67	(973.29)

*Cash and Cash Equivalents comprises the following

Particulars	As at Sept 30,2020	As at March 31,2020
Balances with banks	1,392.23	924.21
Remittance in Transit	-	9.95
Cash on hand	29.31	22.40
Fixed Deposits with maturity of less than 3 months	575.69	5.71
	1,997.23	962.27
Less : Bank Overdraft	153.43	325.60
Cash and Cash Equivalents	1,843.80	636.67

Note: The Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.

X

Nikhil Chopra

Chief Executive Officer & Whole-time director

Date : 10/11/2020
Place : Mumbai



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2020

Sl.No.	PART I - Particulars	Quarter ended			Half year ended		(₹ in lakhs)
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	44,356.43	52,228.50	45,641.70	96,584.93	90,252.73	177,472.91
2	Other Income	839.27	2,268.96	1,850.85	3,108.23	3,111.65	5,066.99
3	Total Income (1+2)	45,195.70	54,497.46	47,492.55	99,693.16	93,364.38	182,539.90
4	Expenses						
a.	Cost of materials consumed	15,207.85	12,660.54	10,582.95	27,868.39	23,200.69	45,248.04
b.	Purchases of stock-in-trade	3,554.20	6,510.24	6,190.59	10,064.44	9,287.56	18,230.77
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,379.17)	(545.21)	(102.98)	(5,924.38)	857.17	(399.27)
d.	Employee benefit expenses	8,107.14	8,866.60	7,702.17	16,973.74	15,507.58	32,291.67
e.	Finance Costs	171.57	374.52	87.39	546.09	167.76	302.96
f.	Depreciation and amortization expense	1,744.64	1,729.39	1,638.65	3,474.03	3,218.44	6,632.23
g.	Other Expenses	11,856.50	9,194.21	11,242.85	21,050.71	21,775.70	44,344.27
	Total Expenses (4)	35,262.73	38,790.29	37,341.62	74,053.02	74,014.90	146,650.67
5	Profit before Exceptional item and Tax (3-4)	9,932.97	15,707.17	10,150.93	25,640.14	19,349.48	35,889.23
6	Exceptional item (Refer Note no. 6)	-	-	-	-	-	1,000.00
7	Profit before Tax (5-6)	9,932.97	15,707.17	10,150.93	25,640.14	19,349.48	34,889.23
8	Tax expenses	2,540.62	3,756.63	774.62	6,297.25	3,762.04	7,650.02
9	Net Profit after Tax for the period (7-8)	7,392.35	11,950.54	9,376.31	19,342.89	15,587.44	27,239.21
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss	(461.44)	(150.00)	(336.77)	(611.44)	(344.77)	(676.74)
	Income tax relating to Items that will not be reclassified to profit or loss	116.14	37.75	83.97	153.89	86.77	170.32
	Items that will be reclassified to profit or loss	(215.57)	416.03	(319.47)	200.46	(122.63)	(991.19)
	Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other Comprehensive Income (net of Tax)	(560.87)	303.78	(572.27)	(257.09)	(380.63)	(1,497.61)
11	Total Comprehensive Income after Tax (9+10)	6,831.48	12,254.32	8,804.04	19,085.80	15,206.81	25,741.60
12	Net Profit after Tax for the period attributable to:						
	- owners of the company	7,382.28	11,942.16	9,362.41	19,324.44	15,563.06	27,204.71
	- non controlling interest	10.07	8.38	13.90	18.45	24.38	34.50
13	Other comprehensive income for the period attributable to:						
	- owners of the company	(569.89)	294.36	(548.54)	(275.53)	(365.99)	(1,432.88)
	- non controlling interest	9.02	9.42	(23.73)	18.44	(14.64)	(64.73)
14	Total Comprehensive Income after Tax attributable to:						
	- owners of the company	6,812.39	12,236.52	8,813.87	19,048.91	15,197.07	25,771.83
	- non controlling interest	19.09	17.80	(9.83)	36.89	9.74	(30.23)
15	Paid up equity Share Capital(Face value of ₹ 2 each)	1,545.64	1,545.64	1,604.73	1,545.64	1,604.73	1,545.64
16	Other Equity	-	-	-	-	-	142,003.29
17	Earning per share (not annualised)						
	(1) Basic in ₹	9.55	15.45	11.67	25.01	19.40	34.20
	(2) Diluted in ₹	9.55	15.45	11.67	25.01	19.40	34.20

Notes:

- The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 10, 2020.
- The statutory auditors have carried out limited review of the consolidated financial results for the quarter ended on September 30, 2020 and their report does not contain any qualification.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- Pursuant to the Share Purchase Agreement (SPA) dated 2nd July 2020 between Tau Investment Holdings Pte. Ltd. (the 'Acquirer') and the Promoter Group (the 'Seller'), the Acquirer has completed the process of open offer made in compliance with Regulation 3(1) and Regulation 4 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and consequently, the Seller has transferred agreed number of shares in favor the Acquirer and the Acquirer now holds 54% of the controlling stake in the Holding Company.
- During the quarter, the Holding Company has acquired Pharmaceutical Business Undertaking of Lekar Pharma Limited, a related party, as going concern, on slump sale basis for a consideration of Rs. 8.50 crores having net current assets of Rs. 4.18 crores and sales revenue of Rs. 56.38 crores for the year ended March 31, 2020.
- Exceptional item appearing in the results for the quarter ended on March 31, 2020 relates to deposit of one-time compensation ordered by the Supreme Court vide judgement dated 1-4-2020 in appeal filed by the Holding Company against Order dated 8-1-2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of the Holding Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle. The Holding Company has since paid this compensation.

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

- 7 With announcement of phased lifting of lockdown in India and globally, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine may take time and hence, the Group continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its Consolidated financial statement. The Group has also considered impact of Covid-19 pandemic on future operations and financial projections. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
- 8 The Code on Social Security, 2020 (the "Code") has been enacted in India. The date of coming into force of the various provisions of the Code is yet to be notified and the rules thereunder are yet to be announced. The potential impact of the change on the Group will be estimated and accounted in the period of notification.
- 9 The Group has one reportable business segment viz. "Pharmaceuticals".
- 10 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

11 STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2020.

STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2020				(₹ in lakhs)
	Particulars	As at September 30,2020	As at March 31,2020	
		Unaudited	Audited	
	ASSETS			
(I)	Non-current assets			
	(a) Property, Plant and Equipment	56,168.96	56,802.98	
	(b) Capital work-in-progress	1,563.79	1,616.69	
	(c) Goodwill	5,745.92	5,314.00	
	(d) Other Intangible assets	3,058.68	3,009.24	
	(e) Financial Assets			
	(i) Investments	1,296.59	6,945.45	
	(ii) Loans	327.50	28.10	
	(iii) Others	7.68	13.23	
	(f) Other non-current assets	617.37	353.58	
	TOTAL non-current assets	68,786.49	74,083.27	
(II)	Current assets			
	(a) Inventories	37,762.16	27,466.97	
	(b) Financial Assets			
	(i) Investments	44,738.54	33,381.26	
	(ii) Trade receivables	41,053.80	34,542.62	
	(iii) Cash and cash equivalents	3,436.94	2,900.79	
	(iv) Bank balances other than (iii) above	198.51	194.02	
	(v) Loans	87.49	421.22	
	(vi) Others	1,171.28	721.07	
	(c) Current Tax Assets (Net)	1,013.87	1,564.00	
	(d) Other current assets	7,115.24	6,080.89	
	TOTAL current assets	136,577.83	107,272.84	
	Total Assets	205,364.32	181,356.11	
	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share capital	1,545.64	1,545.64	
	(b) Other Equity	161,052.20	142,003.29	
	(c) non controlling interest	287.00	250.10	
	Total Equity	162,884.84	143,799.03	
(I)	LIABILITIES			
	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Other financial liabilities	705.42	122.92	
	(b) Provisions	1,978.01	738.68	
	(c) Deferred Tax Liabilities (Net)	4,707.51	4,814.04	
	(d) Other non-current liabilities	518.05	596.84	
	TOTAL non-current Liabilities	7,908.99	6,272.48	
(II)	Current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	3,056.99	3,203.61	
	(ii) Trade payables			
	A) Dues to Micro and Small Enterprises	846.30	945.29	
	B) Due to Other than Micro and Small Enterprises	13,665.93	11,433.96	
	(iii) Other financial liabilities	11,279.67	11,710.49	
	(b) Other current liabilities	3,535.37	2,677.82	
	(c) Provisions	486.11	711.38	
	(d) Current Tax Liabilities (Net)	1,700.12	602.05	
	TOTAL Current Liabilities	34,570.49	31,284.60	
	Total Equity and Liabilities	205,364.32	181,356.11	

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

12 Consolidated Cash Flow Statement for the six months ended 30th September, 2020

(₹ in lakhs)

Particulars	For the period ended Sept. 20		2019-20	
	Unaudited		Audited	
A. Cash Flow from Operating Activities				
Net Profit before Tax		25,640.14		34,889.23
Adjustment For				
Depreciation	3,474.03		6,632.23	
Unrealised Foreign Exchange Fluctuation (Net)	25.60		(633.04)	
Interest expense	532.29		268.91	
(Profit)/ Loss on Sale/Discard of Assets (Net)	67.68		(178.75)	
Profit on sale of Investment designated as FVTPL	(941.57)		(2,501.30)	
Net (Gain)/Loss arising from Financial instruments designated as FVTPL	(1,758.44)		(1,298.40)	
Interest income	(161.56)		(262.10)	
Dividend income	(0.50)		(148.04)	
Government Grant	(82.66)		(91.14)	
Re-measurement of the defined benefit plan	(611.44)		(676.74)	
Excess provision written back	(223.09)		(416.48)	
Discontinuance of Leased Assets	(7.19)		-	
Provision for Doubtful debts/Bad Debts	-		100.34	
		313.15		795.49
Operating Profit Before Working Capital Changes		25,953.29		35,684.72
Adjustment For				
Trade Receivables	(6,426.80)		(3,683.38)	
Other Receivables	(1,457.90)		2,496.34	
Inventories	(10,295.19)		(3,091.20)	
Trade Payables	2,192.86		476.77	
Other Payables & Provisions	1,958.49		4,733.87	
		(14,028.54)		932.40
Cash Generated From Operations		11,924.75		36,617.12
Direct Taxes Paid (Net)		(4,606.12)		(9,079.94)
Net Cash from Operating Activities		7,318.63		27,537.18
B. Cash Flow from Investing Activities				
Purchase of Fixed Assets	(2,420.80)		(7,296.77)	
Sale of Fixed Assets	3.60		246.73	
Goodwill on purchase of business from Lekar Pharma Ltd.	(431.92)			
Purchase of Investment	(17,999.77)		(38,267.56)	
Sale of Investment	14,991.35		47,393.12	
(Increase)/Decrease in other bank balances	(4.49)		(53.99)	
Interest Received	165.67		260.69	
Dividend Received	0.50		148.04	
Net Cash used in Investing Activities		(5,695.86)		2,430.26

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

C. Cash Flow from Financing Activities				
Buy back of shares	-		(16,081.90)	
Proceeds/(Repayment) from/of Short Term Borrowing (Net)	14.35		631.40	
Interest Paid	(508.35)		(186.50)	
Dividend Paid (Including Dividend Distribution Tax)	(0.09)		(14,100.31)	
Lease Rent payment	(419.30)		(867.82)	
Net Cash Used in Financing Activities		(913.39)		(30,605.13)
Net Increase in Cash and Cash Equivalents		709.38		(637.68)
Cash and Cash Equivalents as at 01.04.20*	2,575.19		3,214.16	
Exchange difference on restatement of foreign currency cash and cash equivalent	(1.06)		(1.29)	
Cash and Cash Equivalents as at 30.09.20*	3,283.51	709.38	2,575.19	(637.68)
*Cash and Cash Equivalents comprises the following				
Particulars	As at Sept 30,2020	As at March 31,2020		
Balances with banks	2,831.50	2,862.31		
Remittance in Transit	-	9.95		
Cash on hand	29.75	22.82		
Fixed Deposits with maturity of less than 3 months	575.69	5.71		
	3,436.94	2,900.79		
Less : Bank Overdraft	153.43	325.60		
Cash and Cash Equivalents	3,283.51	2,575.19		
Note: The Consolidated Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows"				

For J.B. Chemicals & Pharmaceuticals Ltd.


Nikhil Chopra

Chief Executive Officer & Whole-time director

Date : 10/11/2020
Place : Mumbai



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of the J. B. Chemicals and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Holding Company") and its Subsidiaries (the Holding Company and Its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2020 and for the year to date period from April 1, 2020 to September 30, 2020 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('Listing Regulations'), which has been initialed by us for the purpose of identification.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors at its meeting held on November 10, 2020, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:

Name of Entity	Relationship
(i). OOO Unique Pharmaceutical Laboratories,	Wholly Owned Subsidiary
(ii). Unique Pharmaceutical Laboratories FZE	Wholly Owned Subsidiary
(iii). Biotech Laboratories (Pty.) Ltd	Subsidiary of Unique Pharmaceutical Laboratories FZE



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial information/ financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total assets of Rs 22,903.89 Lakhs as at September 30, 2020 and total revenue of Rs. 6,989.07 Lakhs and Rs 13,333.72 Lakh, total net profit after tax of Rs. 202.20 Lakhs and Rs 369.61 Lakhs and total comprehensive income/ (Loss) of Rs. (-13.37) Lakhs and Rs 570.07 Lakhs for the quarter ended September 30, 2020 and for the period from April 1, 2020 to September 30, 2020, as considered in the Statement. The unaudited financial information/ financial results of these subsidiaries have been furnished to us as certified by management. Our conclusion, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information/ financial results. According to the information and explanations given to us by the Management, financials of these subsidiaries does not constitute significant component of the group's financial in accordance with circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Our opinion on the Statement is not modified in respect of the above matter.

For D N V & Co.

Chartered Accountants

Firm Registration No 102079W



CA Bharat Jain

Partner

Membership No: 100583

UDIN No: 20100583AAAAGC1072

Place: Mumbai

Date: November 10, 2020



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2020

Sl.No.	PART I - Particulars	Quarter ended			Half year ended		(₹ in lakhs)
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	31/03/2020
1	Revenue from Operations	44,356.43	52,228.50	45,641.70	96,584.93	90,252.73	177,472.91
2	Other Income	839.27	2,268.96	1,850.85	3,108.23	3,111.65	5,066.99
3	Total Income (1+2)	45,195.70	54,497.46	47,492.55	99,693.16	93,364.38	182,539.90
4	Expenses						
a	Cost of materials consumed	15,207.85	12,660.54	10,582.95	27,868.39	23,200.69	45,248.04
b	Purchases of stock-in-trade	3,554.20	6,510.24	6,190.59	10,064.44	9,287.56	18,230.77
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,379.17)	(545.21)	(102.98)	(5,924.38)	857.17	(399.27)
d	Employee benefit expenses	8,107.14	8,866.60	7,702.17	16,973.74	15,507.58	32,291.67
e	Finance Costs	171.57	374.52	87.39	546.09	167.76	302.96
f	Depreciation and amortization expense	1,744.64	1,729.39	1,638.65	3,474.03	3,218.44	6,632.23
g	Other Expenses	11,856.50	9,194.21	11,242.85	21,050.71	21,775.70	44,344.27
	Total Expenses (4)	35,262.73	38,790.29	37,341.62	74,053.02	74,014.90	146,650.67
5	Profit before Exceptional item and Tax (3-4)	9,932.97	15,707.17	10,150.93	25,640.14	19,349.48	35,889.23
6	Exceptional item (Refer Note no. 6)	-	-	-	-	-	1,000.00
7	Profit before Tax (5-6)	9,932.97	15,707.17	10,150.93	25,640.14	19,349.48	34,889.23
8	Tax expenses	2,540.62	3,756.63	774.62	6,297.25	3,762.04	7,650.02
9	Net Profit after Tax for the period (7-8)	7,392.35	11,950.54	9,376.31	19,342.89	15,587.44	27,239.21
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss	(461.44)	(150.00)	(336.77)	(611.44)	(344.77)	(676.74)
	Income tax relating to items that will not be reclassified to profit or loss	116.14	37.75	83.97	153.89	86.77	170.32
	Items that will be reclassified to profit or loss	(215.57)	416.03	(319.47)	200.46	(122.63)	(991.19)
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other Comprehensive Income (net of Tax)	(560.87)	303.78	(572.27)	(257.09)	(380.63)	(1,497.61)
11	Total Comprehensive Income after Tax (9+10)	6,831.48	12,254.32	8,804.04	19,085.80	15,206.81	25,741.60
12	Net Profit after Tax for the period attributable to:						
	- owners of the company	7,382.28	11,942.16	9,362.41	19,324.44	15,563.06	27,204.71
	- non controlling interest	10.07	8.38	13.90	18.45	24.38	34.50
13	Other comprehensive income for the period attributable to:						
	- owners of the company	(569.89)	294.36	(548.54)	(275.53)	(365.99)	(1,432.88)
	- non controlling interest	9.02	9.42	(23.73)	18.44	(14.64)	(64.73)
14	Total Comprehensive Income after Tax attributable to:						
	- owners of the company	6,812.39	12,236.52	8,813.87	19,048.91	15,197.07	25,771.83
	- non controlling interest	19.09	17.80	(9.83)	36.89	9.74	(30.23)
15	Paid up equity Share Capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,604.73	1,545.64	1,604.73	1,545.64
16	Other Equity	-	-	-	-	-	142,003.29
17	Earning per share (not annualised)						
	(1) Basic in ₹	9.55	15.45	11.67	25.01	19.40	34.20
	(2) Diluted in ₹	9.55	15.45	11.67	25.01	19.40	34.20

Notes:

- The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 10, 2020.
- The statutory auditors have carried out limited review of the consolidated financial results for the quarter ended on September 30, 2020 and their report does not contain any qualification.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- Pursuant to the Share Purchase Agreement (SPA) dated 2nd July 2020 between Tau Investment Holdings Pte. Ltd. (the 'Acquirer') and the Promoter Group (the 'Seller'), the Acquirer has completed the process of open offer made in compliance with Regulation 3(1) and Regulation 4 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and consequently, the Seller has transferred agreed number of shares in favor of the Acquirer and the Acquirer now holds 54% of the controlling stake in the Holding Company.
- During the quarter, the Holding Company has acquired Pharmaceutical Business Undertaking of Lekar Pharma Limited, a related party, as going concern, on slump sale basis for a consideration of Rs. 8.50 crores having net current assets of Rs. 4.18 crores and sales revenue of Rs. 56.38 crores for the year ended March 31, 2020.
- Exceptional item appearing in the results for the quarter ended on March 31, 2020 relates to deposit of one-time compensation ordered by the Supreme Court vide judgement dated 1-4-2020 in appeal filed by the Holding Company against Order dated 8-1-2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of the Holding Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle. The Holding Company has since paid this compensation.



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

- 7 With announcement of phased lifting of lockdown in India and globally, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine may take time and hence, the Group continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its Consolidated financial statement. The Group has also considered impact of Covid-19 pandemic on future operations and financial projections. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
- 8 The Code on Social Security, 2020 (the "Code") has been enacted in India. The date of coming into force of the various provisions of the Code is yet to be notified and the rules thereunder are yet to be announced. The potential impact of the change on the Group will be estimated and accounted in the period of notification.
- 9 The Group has one reportable business segment viz. "Pharmaceuticals".
- 10 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

11 STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2020.

(₹ in lakhs)

Particulars	As at September 30,2020	As at March 31,2020
	Unaudited	Audited
ASSETS		
(I) Non-current assets		
(a) Property, Plant and Equipment	56,168.96	56,802.98
(b) Capital work-in-progress	1,563.79	1,616.69
(c) Goodwill	5,745.92	5,314.00
(d) Other Intangible assets	3,058.68	3,009.24
(e) Financial Assets		
(i) Investments	1,296.59	6,945.45
(ii) Loans	327.50	28.10
(iii) Others	7.68	13.23
(f) Other non-current assets	617.37	353.58
TOTAL non-current assets	68,786.49	74,083.27
(II) Current assets		
(a) Inventories	37,762.16	27,466.97
(b) Financial Assets		
(i) Investments	44,738.54	33,381.26
(ii) Trade receivables	41,053.80	34,542.62
(iii) Cash and cash equivalents	3,436.94	2,900.79
(iv) Bank balances other than (iii) above	198.51	194.02
(v) Loans	87.49	421.22
(vi) Others	1,171.28	721.07
(c) Current Tax Assets (Net)	1,013.87	1,564.00
(d) Other current assets	7,115.24	6,080.89
TOTAL current assets	136,577.83	107,272.84
Total Assets	205,364.32	181,356.11
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	1,545.64	1,545.64
(b) Other Equity	161,052.20	142,003.29
(c) non controlling interest	287.00	250.10
Total Equity	162,884.84	143,799.03
LIABILITIES		
(I) Non-current liabilities		
(a) Financial Liabilities		
(i) Other financial liabilities	705.42	122.92
(b) Provisions	1,978.01	738.68
(c) Deferred Tax liabilities (Net)	4,707.51	4,814.04
(d) Other non-current liabilities	518.05	596.84
TOTAL non-current Liabilities	7,908.99	6,272.48
(II) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3,056.99	3,203.61
(ii) Trade payables		
A) Dues to Micro and Small Enterprises	846.30	945.29
B) Due to Other than Micro and Small Enterprises	13,665.93	11,433.96
(iii) Other financial liabilities	11,279.67	11,710.49
(b) Other current liabilities	3,535.37	2,677.82
(c) Provisions	486.11	711.38
(d) Current Tax Liabilities (Net)	1,700.12	602.05
TOTAL Current Liabilities	34,570.49	31,284.60
Total Equity and Liabilities	205,364.32	181,356.11



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 5500
☎ +91 22 2431 5331 / 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

12 Consolidated Cash Flow Statement for the six months ended 30th September, 2020

(₹ in lakhs)

Particulars	For the period ended Sept. 20		2019-20	
	Unaudited		Audited	
A. Cash Flow from Operating Activities				
Net Profit before Tax		25,640.14		34,889.23
Adjustment For				
Depreciation	3,474.03		6,632.23	
Unrealised Foreign Exchange Fluctuation (Net)	25.60		(633.04)	
Interest expense	532.29		268.91	
(Profit)/ Loss on Sale/Discard of Assets (Net)	67.68		(178.75)	
Profit on sale of Investment designated as FVTPL	(941.57)		(2,501.30)	
Net (Gain)/Loss arising from Financial instruments designated as FVTPL	(1,758.44)		(1,298.40)	
Interest income	(161.56)		(262.10)	
Dividend income	(0.50)		(148.04)	
Government Grant	(82.66)		(91.14)	
Re-measurement of the defined benefit plan	(611.44)		(676.74)	
Excess provision written back	(223.09)		(416.48)	
Discontinuance of Leased Assets	(7.19)		-	
Provision for Doubtful debts/Bad Debts	-		100.34	
		313.15		795.49
Operating Profit Before Working Capital Changes		25,953.29		35,684.72
Adjustment For				
Trade Receivables	(6,426.80)		(3,683.38)	
Other Receivables	(1,457.90)		2,496.34	
Inventories	(10,295.19)		(3,091.20)	
Trade Payables	2,192.86		476.77	
Other Payables & Provisions	1,958.49		4,733.87	
		(14,028.54)		932.40
Cash Generated From Operations		11,924.75		36,617.12
Direct Taxes Paid (Net)		(4,606.12)		(9,079.94)
Net Cash from Operating Activities		7,318.63		27,537.18
B. Cash Flow from Investing Activities				
Purchase of Fixed Assets	(2,420.80)		(7,296.77)	
Sale of Fixed Assets	3.60		246.73	
Goodwill on purchase of business from Lekar Pharma Ltd.	(431.92)			
Purchase of Investment	(17,999.77)		(38,267.56)	
Sale of Investment	14,991.35		47,393.12	
(Increase)/Decrease in other bank balances	(4.49)		(53.99)	
Interest Received	165.67		260.69	
Dividend Received	0.50		148.04	
Net Cash used in Investing Activities		(5,695.86)		2,430.26



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025


+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

C. Cash Flow from Financing Activities				
Buy back of shares	-		(16,081.90)	
Proceeds/(Repayment) from/of Short Term Borrowing (Net)	14.35		631.40	
Interest Paid	(508.35)		(186.50)	
Dividend Paid (Including Dividend Distribution Tax)	(0.09)		(14,100.31)	
Lease Rent payment	(419.30)		(867.82)	
		(913.39)		(30,605.13)
Net Cash Used in Financing Activities		709.38		(637.68)
Net Increase in Cash and Cash Equivalents				
Cash and Cash Equivalents as at 01.04.20*	2,575.19		3,214.16	
Exchange difference on restatement of foreign currency cash and cash equivalent	(1.06)		(1.29)	
Cash and Cash Equivalents as at 30.09.20*	3,283.51	709.38	2,575.19	(637.68)
*Cash and Cash Equivalents comprises the following				
Particulars	As at Sept 30,2020	As at March 31,2020		
Balances with banks	2,831.50	2,862.31		
Remittance in Transit	-	9.95		
Cash on hand	29.75	22.82		
Fixed Deposits with maturity of less than 3 months	575.69	5.71		
	3,436.94	2,900.79		
Less : Bank Overdraft	153.43	325.60		
Cash and Cash Equivalents	3,283.51	2,575.19		
Note: The Consolidated Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows"				

For J.B. Chemicals & Pharmaceuticals Ltd.


Nikhil Chopra

Chief Executive Officer & Whole-time director

Date : 10/11/2020
Place : Mumbai



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380